Related references
Note: Only part of the references are listed.
Article
Clinical Neurology
Tamer Roushdy et al.
Summary: This study investigated the availability of stroke care services in African countries, finding that while medications for secondary prevention are available, many other services are lacking.
INTERNATIONAL JOURNAL OF STROKE
(2022)
Article
Cardiac & Cardiovascular Systems
Clayton Long et al.
Summary: There was a significant increase in brain venograms performed following reports of rare CVT cases associated with COVID-19 vaccines, but no CVTs were identified in vaccinated patients. Clinicians should carefully assess the need for brain venogram in COVID-19 vaccinated patients without thrombocytopenia and D-dimer elevation, especially if lacking other CVT risk factors or symptoms.
JOURNAL OF THROMBOSIS AND THROMBOLYSIS
(2022)
Editorial Material
Multidisciplinary Sciences
Serena Spudich et al.
Summary: Understanding the pathophysiological mechanisms behind neurological symptoms is crucial.
Article
Clinical Neurology
Shadi Yaghi et al.
Summary: The study compared the effectiveness of DOACs and warfarin in treating CVT, showing similar outcomes in recurrent venous thrombosis, death, and partial/complete recanalization rates between the two groups, but lower risk of major hemorrhage in the DOACs treatment group.
Article
Clinical Neurology
Thanh N. Nguyen et al.
Summary: In patients undergoing mechanical thrombectomy for proximal anterior circulation stroke in the extended time window, there were no significant differences in clinical outcomes between those selected with noncontrast CT compared to those selected with CTP or MRI. This suggests that noncontrast CT alone may be a simpler alternative for selecting patients with late-presenting large-vessel occlusion for mechanical thrombectomy.
Review
Cardiac & Cardiovascular Systems
Arshia Alimohammadi et al.
Summary: Cerebral venous thrombosis (CVT) is a rare cause of stroke that predominantly affects younger women. Recent literature suggests that direct-acting oral anticoagulants (DOACs) are increasingly being used for CVT management, but guidelines have not yet recommended their routine use. There are ongoing areas of uncertainty around the management of CVT, including the duration of therapy and the potential benefits of neurointervention or personalized antithrombotic strategies for certain patient subgroups.
CURRENT CARDIOLOGY REPORTS
(2022)
Review
Clinical Neurology
James E. Siegler et al.
Summary: This narrative review summarizes the changing paradigms and latest data regarding the complex relationship between COVID-19 and cerebrovascular disease. Despite the association between COVID-19 and thrombotic complications, global declines in ischemic stroke and other cerebrovascular diseases have been observed, which may be attributed to patient avoidance of healthcare institutions and declines in other transmissible infectious illnesses.
Article
Clinical Neurology
James E. Siegler et al.
Summary: COVID-19 is associated with a small but significant risk of cerebrovascular events, particularly ischemic stroke. The mortality rate is high for COVID-19-associated cerebrovascular complications, highlighting the importance of aggressive monitoring and early intervention.
INTERNATIONAL JOURNAL OF STROKE
(2021)
Article
Neurosciences
Alice Ma et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
(2021)
Review
Clinical Neurology
Tommaso Baldini et al.
Summary: This study identified a low number of cases of CVT associated with COVID-19, with symptoms mainly occurring after respiratory disease and involving multiple sites. The occurrence rate of CVT in hospitalized patients with COVID-19 is low but requires a high level of suspicion, as diagnosing this potentially life-threatening condition in COVID-19 patients can be challenging.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Maria E. Ramos-Araque et al.
Summary: This study evaluated clinical predictors of cryptogenic stroke, short-term functional outcomes, and in-hospital mortality among patients with COVID-19 associated stroke. Among 14,483 laboratory-confirmed COVID-19 patients, 1.1% were diagnosed with acute ischemic stroke, with cryptogenic stroke being the most frequently reported etiology.
Review
Neurosciences
Mohamad Abdalkader et al.
Summary: COVID-19 infection can predispose patients to both arterial and venous thromboembolic events, including CVST. Reviewing the clinical and radiological presentation of CVST in COVID-19 positive patients revealed that patients often presented with symptoms like headache, fever, and gastrointestinal symptoms. Clinicians should be vigilant about the risk of acute CVST in patients positive for COVID-19.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
(2021)
Review
Engineering, Biomedical
Ameena Rana et al.
Summary: The COVID-19 pandemic has impacted neurointerventional care for patients with cerebrovascular disease, leading to a global decline in neuroimaging, thrombolysis, thrombectomy, and coil embolization, possibly due to patient and family fears of seeking medical care. As the world rebounds from this crisis, there is hope that the experiences discussed in the research can be transformed into strategies to improve care delivery for neurologically ill patients during global emergencies.
EXPERT REVIEW OF MEDICAL DEVICES
(2021)
Editorial Material
Medicine, General & Internal
Farida B. Ahmad et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Sherry H. -Y. Chou et al.
Summary: This study included patients with clinically diagnosed or laboratory-confirmed COVID-19 at 28 centers across 13 countries and 4 continents from March 1 to September 30, 2020. Neurological manifestations were prevalent among hospitalized patients with COVID-19 and were associated with higher in-hospital mortality. Patients with preexisting neurological disorders were at increased risk of developing neurological signs and/or syndromes in COVID-19.
Article
Clinical Neurology
Vincent Raymaekers et al.
Summary: A decline in stroke hospitalizations during the COVID-19 pandemic in Belgium was observed, but the quality parameters of stroke care remained unchanged.
ACTA NEUROLOGICA BELGICA
(2021)
Article
Medicine, General & Internal
Mayte Sanchez van Kammen et al.
Summary: Cases of cerebral venous sinus thrombosis with thrombocytopenia have been reported following vaccination with AstraZeneca/Oxford and Janssen/Johnson & Johnson COVID-19 vaccines. A potential immune-mediated response involving platelet factor 4/heparin antibodies has been suggested as the underlying mechanism. This study found that baseline thrombocytopenia, heparin-induced thrombocytopenia, and platelet factor 4/heparin antibodies were uncommon in patients diagnosed with cerebral venous sinus thrombosis before the COVID-19 pandemic.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Medicine, General & Internal
Maxime Taquet et al.
Summary: This study found that the incidence of cerebral venous thrombosis and portal vein thrombosis after a COVID-19 diagnosis was significantly higher than in cohorts of individuals who received mRNA vaccines or had influenza.
Review
Clinical Neurology
Stefania Nannoni et al.
Summary: Acute cerebrovascular diseases occur in 1.4% of COVID-19 patients, with acute ischemic stroke being the most common manifestation. Patients with COVID-19 are more likely to have pre-existing vascular risk factors and higher mortality rates compared to those without cerebrovascular diseases.
INTERNATIONAL JOURNAL OF STROKE
(2021)
Article
Cardiac & Cardiovascular Systems
Moritz Seiffert et al.
CLINICAL RESEARCH IN CARDIOLOGY
(2020)
Review
Neurosciences
Felix Nwajei et al.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
(2020)
